|
On or about (b)(6) 2024, plaintiff underwent placement of an angiodynamics smartport port catheter product, with model number h787ct80stpd0, and lot number 5821731.This smartport device consisted of a port body and a polyurethane catheter.The smartport device was implanted by dr.(b)(6) md.Under the supervision of dr.(b)(6) md., at (b)(6), for the purpose of ongoing chemotherapy treatment.On or about (b)(6) 2025, plaintiff (b)(6) presented to (b)(6) hospital in (b)(6), with complaints of fever since that morning.She was admitted with concern for neutropenic fever with sepsis and hospital- acquired pneumonia.Blood cultures from the port were positive for staphylococcus epidermidis likely contaminant at port site.Blood cultures drawn on (b)(6) 2025, from the port site, were positive for staphylococcus epidermidis in 1 of 2 bottles.Found to have methicillin resistant staphylococcus epidermidis bacteria in one bottle.On or about (b)(6) 2025, medical recommendation was to discontinue vancomycin given negative mrsa nares swab.Continue cefepime.Discontinue blood culture collection.The assessment at the time was that patient is colonized or contaminant at port site vs low concern for clabsi.Plaintiff continued her hospital stay until (b)(6) 2025, when she was finally discharged.
|